Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials

BACKGROUND AND OBJECTIVES: Upadacitinib is a janus kinase (JAK) 1 inhibitor being developed for the treatment of rheumatoid arthritis (RA) and other inflammatory diseases. This work characterized upadacitinib population pharmacokinetics in healthy subjects and RA patients and the effects of covariat...

Descripción completa

Detalles Bibliográficos
Autores principales: Klünder, Ben, Mohamed, Mohamed-Eslam F., Othman, Ahmed A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6028884/
https://www.ncbi.nlm.nih.gov/pubmed/29076110
http://dx.doi.org/10.1007/s40262-017-0605-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6028884/
https://www.ncbi.nlm.nih.gov/pubmed/29076110
http://dx.doi.org/10.1007/s40262-017-0605-6

Ejemplares similares